ScreenerHero

NRSN NeuroSense Therapeutics Ltd.

NAS · US · Healthcare · Biotechnology · neurosense-tx.com
3.820USD-6.14%Mkt Cap: 7.25M $P/E: —

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap7.25M USD
Enterprise Value7.20M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-11.13M USD
Revenue/Share—
Last Price3.820 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.35
PEG—
EV/EBITDA-0.65
EV/Revenue—
P/S—
P/B-4.25
EPS (TTM)-47.10
EPS (Forward)-11.76
52W Range
3.7900% of range26.64
52W High26.64 USD
52W Low3.790 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE713.14%
ROA-1082.20%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.67M USD
CapEx (TTM)8.00K USD
FCF Margin—
FCF Yield-53.40%
Net Debt4.00K USD
Net Debt/EBITDA-0.00
Balance Sheet
Debt/Equity-0.11
Current Ratio0.31
Quick Ratio0.08
Book Value/Sh-0.96 USD
Cash/Share0.09 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateSep 14, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)97.33 USD
Upside (mean)+2448.0%
Target Range52.00 USD – 180.00 USD
52.00+2448.0% to mean180.00
# Analysts3
Ownership
Shares Out.1.90M
Float1.19M
Insiders31.42%
Institutions1.05%
Short Interest
Short Ratio1.3d
Short % Float2.56%
Short % Out.2.02%
Shares Short38.24K
Short (prev mo.)24.46K
Technical
SMA 507.928 (-51.8%)
SMA 20014.25 (-73.2%)
Beta1.64
S&P 52W Chg15.78%
Avg Vol (30d)27.86K
Avg Vol (10d)27.89K
Technical Indicators
RSI (14)27.5
MACD-1.3308
MACD Signal-1.1756
MACD Hist.-0.1552
BB Upper9.778 USD
BB Middle6.180 USD
BB Lower2.583 USD
BB Width116.42%
ATR (14)0.9801 USD
Vol Ratio (20d)0.38x